IRVINE, Calif., Feb. 17, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its fourth quarter 2010 financial results on Thursday, February 24, 2011. Results will be released at the close of trading on that day.
A conference call has also been scheduled regarding CombiMatrix Corporation's fourth quarter and 2010 annual financial results. The presentation and Q&A session will start at 1:30 p.m. Pacific Time (4:30 p.m. Eastern) on February 24, 2011.
To attend the presentation by phone, dial 1-888-857-6929 for domestic callers and 1-719-457-2647 for direct dial or international callers. To listen to the call via CombiMatrix's website, go to www.combimatrix.com , in the Investor/Events section, ( http://investor.combimatrix.com/events.cfm ).A replay of the presentation will be available for 14 days, either via the CombiMatrix website Investor/Events section ( http://investor.combimatrix.com/events.cfm ) or by dialing 1-877-870-5176 for domestic callers or 1-858-384-5517 for direct dial international callers. When prompted, enter playback pin number 3689027. The call will also be webcast live and can be accessed at CombiMatrix's website at www.combimatrix.com , in the Investor/Events section, ( http://investor.combimatrix.com/events.cfm ). About Combimatrix Corporation CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Diagnostics, is a CAP/CLIA certified molecular diagnostics laboratory offering comprehensive profiling of chromosomes and genes for both oncology and pre- and postnatal developmental disorders. CombiMatrix Diagnostics offers a comprehensive and proprietary analysis of cancer tumors at the DNA, or molecular level. The Company was the first clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to all oncology patients and medical professionals. The Company also offers pre- and postnatal testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies such as ultrasound examinations and amniocentesis. Additional information about CombiMatrix Corporation is available at www.combimatrix.com . Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.
CONTACT: Company Contact: R. Judd Jessup President & CEO, CombiMatrix Corporation Tel (949) 753-0624 Investor Relations Contact: Matthew H. Clawson Partner, Allen & Caron, Inc. Tel (949) 474-4300 firstname.lastname@example.org